Telcon RF Pharmaceutical prepays KRW 2.81 billion convertible debt via repurchase

Telcon RF Pharmaceutical will repurchase KRW 2.81 billion of its 23rd private convertible bonds ahead of maturity, covering KRW 2.7 billion in face value via an off-market purchase under an early redemption agreement, with payment set for Sept. 29, 2026.